Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03563157
Recruitment Status : Active, not recruiting
First Posted : June 20, 2018
Last Update Posted : May 17, 2019
Sponsor:
Information provided by (Responsible Party):
NantKwest, Inc.

Tracking Information
First Submitted Date  ICMJE May 22, 2018
First Posted Date  ICMJE June 20, 2018
Last Update Posted Date May 17, 2019
Actual Study Start Date  ICMJE May 25, 2018
Estimated Primary Completion Date December 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 15, 2018)
  • Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03 [ Time Frame: 2 years ]
    Phase 1b
  • Progression Free Survival from baseline to progression, per RECIST 1.1 [ Time Frame: 2 years ]
    Phase 2 Randomized Component
  • Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1 [ Time Frame: 1 year ]
    Phase 2 Single Arm Component
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03563157 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 15, 2018)
  • ORR for Phase 1b and Phase 2 Randomized Component [ Time Frame: 1 year ]
    Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC
  • PFS for Phase 1b and Phase 2 Single Arm Component [ Time Frame: 2 years ]
    Progression Free Survival from baseline to progression per RECIST 1.1 and irRC
  • OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
    Overall Survival from first treatment to date of death (any cause)
  • DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
    Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC
  • DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 1 year ]
    Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC
  • QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
    Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Official Title  ICMJE NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
Brief Summary QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib in Subjects with CRC Who have Previously Treated with SOC.
Detailed Description NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with Standard-Of-Care Therapy
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Colorectal Cancer Metastatic
  • mCRC
Intervention  ICMJE
  • Biological: Aldoxorubicin Hydrochloride
    Aldoxorubicin Hydrochloride HCI
  • Biological: ALT-803
    Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
  • Biological: ETBX-011
    Ad5 [E1-, E2b-]-CEA
  • Biological: ETBX-021
    Ad5 [E1-, E2b-]-[HER2]
  • Biological: ETBX-051
    Ad5 [E1-, E2b-]-Brachyury
  • Biological: ETBX-061
    Ad5 [E1-, E2b-]-mucin 1 [MUC1]
  • Biological: GI-4000
    RAS yeast
  • Biological: GI-6207
    CEA yeast
  • Biological: GI-6301
    Brachyury yeast
  • Biological: haNK
    haNK™, NK-92 [CD16.158V, ER IL-2]
  • Drug: Avelumab
    BAVENCIO® injection
  • Drug: Capecitabine
    XELODA® tablets
  • Drug: Cetuximab
    ERBITUX® injection
  • Drug: Cyclophosphamide
    Cyclophosphamide Capsules
  • Drug: 5-Fluorouracil
    5-FU; Fluorouracil Injection
  • Drug: Leucovorin
    Leucovorin Calcium
  • Drug: Nab-paclitaxel
    ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
  • Drug: Oxaliplatin
    ELOXATIN® injection
  • Drug: Regorafenib
    STIVARGA® tablets
  • Procedure: SBRT
    Stereotactic body radiation therapy
Study Arms  ICMJE
  • Experimental: NANT Colorectal Cancer (CRC) Vaccine
    A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
    Interventions:
    • Biological: Aldoxorubicin Hydrochloride
    • Biological: ALT-803
    • Biological: ETBX-011
    • Biological: ETBX-021
    • Biological: ETBX-051
    • Biological: ETBX-061
    • Biological: GI-4000
    • Biological: GI-6207
    • Biological: GI-6301
    • Biological: haNK
    • Drug: Avelumab
    • Drug: Capecitabine
    • Drug: Cetuximab
    • Drug: Cyclophosphamide
    • Drug: 5-Fluorouracil
    • Drug: Leucovorin
    • Drug: Nab-paclitaxel
    • Drug: Oxaliplatin
    • Drug: Regorafenib
    • Procedure: SBRT
  • Active Comparator: Regorafenib
    In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
    Intervention: Drug: Regorafenib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: June 15, 2018)
332
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 30, 2021
Estimated Primary Completion Date December 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines.
  3. Histologically-confirmed recurrent or metastatic CRC previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy; or subjects who are ineligible for these therapies.
  4. ECOG performance status of 0 or 1.
  5. Have at least 1 measurable lesion of ≥ 1.0 cm.
  6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  7. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.
  8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, and abstinence.

    Phase 2 single-arm component only

  11. Must have progressed on or after regorafenib treatment in the randomized phase 2 portion of the study OR progressed or experienced unacceptable toxicity on SoC and regorafenib prior to enrollment on the study.

Exclusion Criteria:

  1. MSI-high or MMR-deficient tumors eligible for, but not yet treated with, a PD-1 inhibitor.
  2. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drugs used in this study or that would put the subject at high risk for treatment-related complications.
  3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma).
  4. History of organ transplant requiring immunosuppression.
  5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  6. Inadequate organ function, evidenced by the following laboratory results:

    1. ANC < 1,000 cells/mm^3.
    2. Uncorrectable grade 3 anemia (hemoglobin < 8 g/dL)
    3. Platelet count < 75,000 cells/mm^3.
    4. Total bilirubin > ULN (unless the subject has documented Gilbert's syndrome).
    5. AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
    6. ALP > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
    7. Serum creatinine > 2.0 mg/dL or 177 μmol/L.
    8. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3.
  7. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
  8. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the institution's lower limit of predicted normal.
  9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
  10. Positive results of screening test for HIV.
  11. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  12. Known hypersensitivity to any component of the study medication(s).
  13. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  14. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
  15. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
  16. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
  17. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  18. Concurrent participation in any interventional clinical trial.
  19. Pregnant and nursing women.

    Phase 2 randomized component only

  20. Prior regorafenib treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03563157
Other Study ID Numbers  ICMJE QUILT-3.071
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party NantKwest, Inc.
Study Sponsor  ICMJE NantKwest, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account NantKwest, Inc.
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP